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Abstract
Background: The use of antipsychotic medications (APMs) in nursing home residents in the U.S. is an increasingly
prominent issue and has been associated with increased risk of hospitalization, cardiovascular events, hip fractures,
and mortality, among other adverse health events. The Food and Drug Administration has placed a black box
warning on these drugs, specifying that they are not meant for residents with dementia, and has asked providers to
review their treatment plans. The purpose of this systematic PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-analyses)-based review was to summarize original research studies on facility level characteristics
contributing to the use of antipsychotics in nursing homes across the United States, in order to investigate the
variation of use.
Methods: We searched Ovid Medline, Embase, Cochrane Library, Web of Science, CINAHL, PsycInfo, and
Sociological Abstracts. Articles were selected according to the following criteria: (1) Population of interest: older
adults (≥60 years of age) residing in nursing homes (not home-based or inpatient hospital settings) in the U.S. (2)
Receiving APMs, typical and/or atypical. Specifically excluded were studies of psychotropic medications such as
antidepressants, benzodiazepines, anxiolytics, hypnotics, mood stabilizers, and stimulants. All study designs were
considered, though reviews, editorials, letters to the editor and opinion pieces were excluded. An expert consultant
panel was consulted to categorize facility characteristics into domains and determine possible etiologies of APM
use based upon each characteristic.
Results: Nineteen observational studies, both quantitative and qualitative, published from 2000 to 2015, met full
inclusion criteria and were included in this review. APM use varied based on multiple facility characteristics across
several domains: 1) physical, 2) staffing, 3) occupancy, 4) market, and 5) quality.
Conclusions: Variation in use of APMs in U.S. nursing homes based upon facility characteristics exemplifies the
need for a more systematic protocol guiding the use of these medications, along with heightened regulatory
policies and enforcement.
Keywords: Antipsychotics, Nursing homes, Dementia, Behavioral symptoms
* Correspondence: hstocker@aging.arizona.edu
1College of Public Health, University of Arizona, Tucson, Arizona, USA
2Arizona Center on Aging, College of Medicine, University of Arizona, Tucson,
Arizona, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cioltan et al. BMC Geriatrics  (2017) 17:32 
DOI 10.1186/s12877-017-0428-1
Background
The 1987 Omnibus Budget Reconciliation Act’s Nursing
Home Reform Law, was enacted to improve patient-
centered nursing home care quality, and included stan-
dards regarding freedom from unnecessary drugging;
freedom from chemical restraints; and rights to be in-
formed about, participate in, and refuse treatment [1].In
2005, the Food and Drug Administration (FDA) placed a
black box warning on antipsychotic medications (APMs)
use in elderly patients because of the dangerous health
outcomes associated with use including mortality [2]. In
a 2011 report from the Office of Inspector General, it
was determined 83% of Medicare claims for APMs in
nursing home residents were associated with off-label
conditions [3]. Following this, in March 2012, the Cen-
ters for Medicare and Medicaid Services (CMS)
launched an education and training, and oversight and
provider accountability initiative targeted to provide ap-
propriate, resident-centered dementia care to decrease
the use of APMs in nursing homes nationwide by 15%.
CMS added two quality measures on the Nursing Home
Compare website related to APMs including the percent
of long-stay residents who received an APM [4]. Despite
these gains, APM use in elderly nursing home patients
has continued, with 1 in 5 nursing home residents
treated with APMs [5]. This problem will only grow in
magnitude if not addressed. By 2050 the population of
older adults aged 65 and older is projected to reach 83.7
million, almost doubling the estimated 2012 elder popu-
lation of 43.1 million [6]. In 2012 15,700 nursing homes
served 1.4 million residents; the number of elders resid-
ing in nursing homes will only increase with our increas-
ing older population [7].
APMs are approved by the FDA for the treatment of
schizophrenia and/or bipolar disorder but are increas-
ingly used to treat the behavioral symptoms of dementia,
an off-label use [3]. In the years between 1995 and 2008
such off-label use more than doubled [8]. The effective-
ness of APMs for off-label use to treat behavioral symp-
toms of dementia is not supported by strong evidence
and the use of APMs in patients with dementia increases
the risk of adverse health events with little evidence of
effectiveness [9, 10].
The use of APMs is not only a concern in the U.S. but
also internationally. In the United Kingdom, a study in-
cluding 12 nursing homes found 48% of patients with
dementia were prescribed APMs [11], while a provider
of pharmaceutical market information showed that
20.3% of patients with dementia had a prescription for
APMs [12]. A report for the Minister of State for Care
Services in the United Kingdom called for a national
campaign to reduce APM use, citing the limited positive
and significant harm causing effects of the drugs [13].
These drugs are also commonly used in the treatment of
dementia in nursing homes across western Europe with
rates ranging from 12 to 59%, although the clinical
guidelines and warnings from European and national
drug agencies suggest lowering use in this population
[14]. Initiatives to reduce the use of APMs in the treat-
ment of patients with dementia are increasingly preva-
lent in the U.S. and abroad—spurred by the continued
high rates of use of these agents.
Adverse health outcomes associated with APM use in
the elderly population include increased risk of falls,
hospitalizations, cerebrovascular events, sudden cardiac
death, and mortality [15]. APM use in patients with de-
mentia is associated with a significant increased risk of
stroke (OR, 3.12), cardiovascular symptoms, edema, and
vasodilatation [15]. Also, the rate of sudden cardiac
death among atypical antipsychotic users compared to
nonusers is higher with an adjusted incidence-rate ratio
of 2.26 [16]. It is vital that we reduce unnecessary use in
this population because of the association between APM
use and all-cause mortality. A meta-analysis of 15 ran-
domized control trials, with 3,353 patients randomized
to APMs and 1,757 randomized to placebo, showed that
death occurred more frequently during the study period
in patients randomized to APMs (OR, 1.54) with a num-
ber needed to harm of 100 [17].
Although previous legislation has aimed to reduce off-
label use of APMs in elderly nursing home residents,
prevalence remains high. It is crucial that facility level
factors associated with APM use in this population be
identified and understood in order to be able to recom-
mend interventions to decrease dangerous use in an effi-
cient an effective manner. The purpose of this
systematic review was to summarize original research
studies on the facility level characteristics contributing
to the use of APMs in nursing homes across the U.S.
Methods
Study selection
A literature review was planned and performed using
methods specified in the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) state-
ment for reporting systematic reviews and meta-analyses
however a meta-analysis was not performed [18]. Both
controlled vocabulary terms (e.g., MeSH) and key words
were utilized to search the following databases Ovid/
MEDLINE (1946–2015); Elsevier/Embase (1947–2015);
Wiley/Cochrane Library (1898–2015); Thomson-
Reuters/Web of Science (1898–2015); EBSCO/PsycINFO
(1880’s-2015); EBSCO/CINAHL (1937–2015); and Pro-
Quest/Sociological Abstracts (1952–2015). Literature
searches were completed on July 10, 2015. The complete
Ovid/MEDLINE search strategy, analogous to the other
database searches, is available in Additional file 1. Refer-
ence lists of, and citations to, the articles eventually
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selected from the database searches were also screened.
Only English language publications were selected and, in
the case of both CINAHL and PsycInfo, article types
were limited to Academic Journals and Dissertations.
Included studies focused on population of interest: 1)
older adults (≥60 years of age) residing in nursing homes
(not home-based or inpatient hospital settings) in the
U.S.; and 2) those who received APMs, typical and/or
atypical. Specifically excluded were studies of psycho-
tropic medications such as antidepressants, benzodiaze-
pines, anxiolytics, hypnotics, mood stabilizers, and
stimulants alone or in combination with APMs where
the antipsychotic component could not be isolated. All
study designs were considered although reviews, edito-
rials, letters to the editor and opinion pieces were ex-
cluded. No publication or language limits were applied,
though ultimately only articles in English were selected.
Nursing homes were defined as facilities recognized by
the Medicare and Medicaid systems offering skilled
nursing care including rehabilitation and various medical
and nursing procedures.
Titles and abstracts of retrieved references were
screened for relevance by two independent reviewers
(HC and SA), one trained in public health and gerontol-
ogy, and the other in gero-pharmacy. In case of disagree-
ments, a third reviewer (CH) cast the deciding vote. In
the same fashion, the full texts of the potential studies
were further analyzed by two independent reviewers
(HC and SA) to see if they fully met inclusion criteria.
Disagreements at this stage were resolved by consensus
and in consultation with a third reviewer (CH).
Data extraction
The reviewers (HC and SA) extracted the following data
from the included articles: type and number of subjects,
study design, the year of publication, journal of publica-
tion, U.S. regions included in the assessment, and the fa-
cility characteristics associated with the use of APMs.
The summary outcome measure considered for this re-
view was any association between facility characteristic
and APM use.
Quality assessment
The selection process ensured that all articles included
in the analysis were from peer-reviewed journals. All
observational cross-sectional or cohort studies were
assessed for alignment with the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) statement to enhance rigor [19].
Data analysis
The facility characteristics shown to have an effect on
the use of APMs were categorized into domains based
upon categorization found in the included studies and
through iterative content analysis with expert feedback from
a nursing home expert consensus group of 20 experts com-
prised of nursing home administrators, pharmacists, an epi-
demiologist, a neurologist, two geriatricians, a nursing home
medical director, a nursing home nurse educator, and
Healthy Brain Research Network Collaborating Centers in
five states (Table 1). The facility characteristics considered
were extracted from the included studies. A modified Delphi
method was used to ensure structure in categorizing the
characteristics into domains as well as determining the pos-
sible etiologies of APM use based on each facility character-
istic contributing to use. The rationale for increased APM
use was also extracted from the studies when available.
Results
Study selection
We found 8,164 studies through database searches. Citation
analysis of the most relevant articles revealed an additional
15 articles. Of the 5,704 articles that remained after dupli-
cates were removed, 5,641 were excluded because of irrele-
vance to the topic (Fig. 1). Strict inclusion criteria, as
outlined above, were applied to the full text of 63 articles.
Of these, 19 met the full set of criteria (Table 2) [20–38].
All articles were published between 2000 and 2015, during
which time there were several legislative, regulatory and
policy changes related to use of antipsychotics as discussed
in the Background Section. Please see Additional file 2 for
completed PRISMA checklist.
Study design and quality assessment
All 19 peer-reviewed articles were observational (either
cross-sectional or cohort studies) or qualitative, from en-
tities including: the Journal of the American Medical
Table 1 Expert panel details
Expert Profession








Debbie Dyjak RN educator in nursing
home
Lee Olitsky Nursing home
administrator
Beverly Heasley Nursing home
administrator
University of Arizona, University of Washington,
University of Pennsylvania, University of South
Carolina, Oregon Health and Science University,
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Association; the Journal of the American Geriatrics So-
ciety; the American Journal of Public Health; Drugs &
Aging; Health Economics; Journal of Health and Social
Policy; among several others. The included observa-
tional studies consisted of cross-sectional, retrospective
cohort and longitudinal studies by design. The specific
outcome measures included: differences of APM use in
nursing homes based upon facility characteristics ([20–
23, 25, 27, 31, 33, 34, 36–38]; odds ratios ([24, 28–30,
32, 33, 35]; beta values [26]; and risk ratios [25]. The ar-
ticles included aligned with the STROBE statement on
what should be included in a report of an observational
study [19].
Subjects and representative sample
The sample sizes ranged from 204 to 155,095 partici-
pants and 16 to 17,213 nursing homes (Table 2). All par-
ticipants were nursing home residents aged 60 years or
older. Many of the studies used the Online Survey,
Certification and Reporting (OSCAR) database or the
Minimum Data Set (MDS). MDS and OSCAR are two
national systems that collect nursing home quality infor-
mation required by CMS. MDS collects information
about nursing home residents and OSCAR about the
facility [39].
Facility characteristics associated with APM use
Table 3 depicts the characteristics associated with use of
APMs: 1) physical facility characteristics such as geo-
graphic location; 2) staffing characteristics including staff
to patient ratios and type of staffing; 3) occupancy char-
acteristics such as occupancy rate; 4) market characteris-
tics such as the presence of competition; and 5) quality
characteristics, for example, the regulatory reporting of
physical restraint use.
Fig. 1 Flowchart of the process of literature search and extraction of studies meeting the inclusion criteria
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The physical characteristics associated with use of
APMs were: 1) physical location, specifically whether the
facility was in an urban setting or not and/or its specific
geographic location in the country; 2) facility size; 3)
profit status; and 4) presence of acuity services [23–26,
29, 31–33, 35]. The staffing characteristics included: 1)
staffing ratios; 2) behavioral health (BH) expertise; and
3) social services support [16, 20, 26, 32, 33, 36, 37].
Occupancy characteristics involved the resident mix and
occupancy rate [20, 24, 26, 32, 33, 35]. Market character-
istics associated with APM use in nursing homes
included competition and chain membership [24].
Finally, the two quality characteristics associated with
higher use were 1) facilities subject to the reporting of
physical restraints and 2) facilities with a higher number
of deficiencies [21, 32, 38].
Several facility characteristics were reported more
frequently than others in our included studies. The posi-
tive associations between both lower RN staffing and in-
creasing facility share of Medicaid residents with APM
use were each reported in four different studies (Table 3)
[24, 26, 32, 33, 35, 36]. Also, the associations between
APM use and each of the characteristics: geographical
location and for-profit status were shown in five separate
studies [23–26, 32, 33, 35].
Discussion
The purpose of the current systematic review was to
study the association between facility characteristics and
the use of APM among older adults residing in U.S.
nursing homes. Facility-based characteristics that are as-
sociated with APMs use in U.S. nursing homes may be
categorized into several domains: 1) physical, 2) staffing,
3) occupancy, 4) market, and 5) quality (Table 3).
The current systematic literature review revealed many
facility level characteristics that play a role in increasing
the use of APMs in the nursing home population. Inves-
tigating these characteristics is important because vari-
ation based upon facility characteristics could indicate
the absence of a nationally consistent and systematic ap-
proach to the use of APMs in nursing homes. In order
to inform possible interventions to reduce the unneces-
sary use of APMs, it is important to understand the as-
sociated domains of the characteristics as well as the
possible reasoning behind the increased use. The
complete list of explanations for increased APM use
based upon each characteristic are specified in Table 3.
Physical characteristics
The physical characteristics associated with APM use in-
cluded physical location, facility size, business type, and
the presence of acuity services. Regional variation in
APM use was evident with a positive association be-
tween APM use and facility location in the central south
or northeast U.S. regions [23, 25, 26, 29]. However, one
study by Briesacher et al., 2005 expressed a negative
association between APM use and nursing homes in the
southern United States [22]. It was also found that facil-
ities in the southern U.S. tended to prescribe conven-
tional APMs whereas facilities in the northeastern U.S.
prescribed atypical APMs [27]. This positive association
between APMs and facilities in the south or northeast
U.S. regions could be due to different state laws and
regulation or regionally differing treatment approaches
of behavioral symptoms of dementia. A positive associ-
ation between metropolitan location and APM use was
evident and these facilities were more likely to prescribe
atypical APMs [27, 35]. Increased facility size was con-
versely negatively associated with APM use, indicating
that larger facilities may have more ability to implement
change processes or provide more comprehensive ser-
vices as a result of economies of scale [25, 26, 29]. Lar-
ger facilities were also more likely to prescribe atypical
APMs rather than conventional [27]. Five articles in-
cluded evidence that for-profit facilities were positively
associated with APM use [24, 26, 31–33]. Kamble et al.
found a positive association between the off-label use of
APMs and non-profit facilities [30]. Finally, the presence
of acuity services was positively associated with the use
of APMs, possibly due to larger proportion of residents
with more complex medical conditions and behavioral
symptoms [26]. Huybrechts et al. found that facilities
with Alzheimer special care units more often prescribed
atypical APMs [27].
Staffing characteristics
Staffing characteristics play a pivotal role in the in-
creased use of APMs in nursing homes and include: 1)
staffing ratios; 2) the presence of mental health profes-
sionals or physicians; and 3) the presence of social
services (Table 3). Registered nurse (RN) staffing plays a
critical role in the increased use of antipsychotics with a
positive association between decreased RN staffing and
APM use [26, 32, 33, 36]. Less time is available per pa-
tient when nursing staff to patient ratios are low, and
APMs may serve as a cost-saving alternative to hiring
additional RNs. Interestingly, licensed practical nurse
(LPN) to patient ratios have the opposite effect on the
use of antipsychotics. A positive relationship between
LPNs and APMs exists [32]. We theorize that the differ-
ence in training between an LPN and RN could play a
role in such association.
In addition to nurse staffing ratios, the presence of
mental health professionals, physicians and social ser-
vices all affect the use of APMs with the presence of
mental health professionals positively associated with
APM use [20, 26, 32]. Facilities with mental health staff
were also more likely to prescribe atypical APMs [27].
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This positive association could be explained by a greater
percentage of residents with behavioral problems in
nursing homes where mental health professionals are
more available or to the practice patterns of mental
health professionals and physicians. Conversely, the
presence of social services was negatively associated with
the use of APMs. This may be caused by increased
patient-clinician face time or by the inclusion of the
family in decision-making [20]. It is important to note
that Lucas et al. found no association between the pres-
ence of mental health staff and APM use [32]. A
complete list of staffing characteristics and etiologies of
use can be found in Table 3. Overall, it appears that the
more time that staff is able to spend with the patients in
nursing homes, the less likely it is that APMs are used.
Occupancy characteristics
Both the resident mix and occupancy rate of a facility
contributed to variation of APM use among facilities
[20, 24, 26, 32, 33, 35]. Facilities with a greater facility
share of Medicaid residents were positively associated
with APM use [24, 26, 32, 35]. Medicaid reimbursement
rates are on average 70% of private-pay reimbursement
rates and considerably influence the resources available
in nursing homes [40]. Consequently, APMs may be
used to minimize resource use, or be used as a result of
lower staffing levels or insufficient training. Kamble et
al. found, however, that Medicaid patients were nega-
tively associated with off-label APM use [30]. Low occu-
pancy rate was positively associated with APM use,
again probably due to a decreased availability of funds to
increase staffing, education and/or training [26]. It may
be reasonable to assume that the quality of care goes
down when facility care capacities are exceeded. Also, a
lower Medicare census, increased racial diversity, and
self-pay patients were positively associated with APM
use according to several studies [20, 30, 33, 35]. Finally,
it is important to note that one study found that pay-
ment source does not affect the use of APMs [28]. The
occupancy characteristic etiologies of increased APM
use were commonly related to fewer resources and lim-
ited funding.
Market characteristics
Two market characteristics, independent ownership and
minimal competition, were positively associated with use
of APMs in U.S. nursing homes [24]. Competition may
reduce APM use by forcing nursing homes to improve
or maintain higher quality to maintain occupancy. Inde-
pendent ownership may contribute to increased rates of
use as a result of a lack of standardization, accountability
and oversight [24]. Interestingly, Pimentel et al. found
that pharmaceutical marketing was not significantly
associated with the use of antipsychotics [34].
Quality characteristics
Facilities subject to reporting physical restraint use and
with higher numbers of deficiency citations were posi-
tively associated with APM use [21, 32, 38]. Requiring
nursing homes to report physical restraints was posi-
tively associated with APM use, possibly due to the fact
that APMs, presumed to have fewer adverse effects,
were used as a substitute [38]. The number of citations
received at a nursing home was also positively associ-
ated with APM use [32]. It has been previously shown
that lower quality is associated with increased citations
[21, 32]. It is possible that the nursing homes might
have a multitasking incentive problem, wherein the
efforts to improve quality are spread to many areas of
concern and could lead to not adequately addressing
the use of APMs [21].
Policy and management implications
Despite multiple legislative and educational interven-
tions, including the 1987 Omnibus Budget Reconcili-
ation Act’s Nursing Home Reform Law, the FDA’s
black box warning on antipsychotic medications, the
Centers for Medicare and Medicaid Services campaign
to decrease the use of antipsychotics in nursing homes
nationwide, and the Nursing Home Compare website
related to antipsychotics, it is clear that much work re-
mains to be done. It is a promising sign however, that
the government initiatives have influenced and in-
creased research surrounding the topic. The majority
of the studies included in this review were published
between 2006 and 2012 after the black box warning
was issued. Many of these studies focus on the facility
characteristics included in the national OSCAR data-
base, which surveys revenue sources, ownership, staff-
ing, resident mix and deficiency reporting. The studies
published after 2012, the year CMS launched an initia-
tive to decrease use, investigate additional nursing
home characteristics that influence APM use includ-
ing: consultant psychiatry, pharmaceutical marketing,
physical restraint deficiency reporting, and the pres-
ence of social services (Additional file 3). All of these
studies provide valuable information about the use of
APMs in the nursing home population in the U.S. Pol-
icy and management interventions to reduce the un-
necessary use of APMs in elderly nursing home
patients should focus on the facility and quality char-
acteristics associated with use and address the root
causes of excessive use of these dangerous drugs. The
variation in use based upon staffing, market, physical,
and quality characteristics of the nursing homes illus-
trates the need for a strict and systematic approach to
APM use. Facility characteristics discussed in this re-
view could inform meaningful and evidence-based in-
terventions that would result in reduced use of APMs
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and the serious and poor health outcomes associated
with their use.
International implications
The findings of this literature review can benefit an
international audience, as high rates of APM use in
nursing homes are common not only in the U.S. but in
other nations as well. Although skilled nursing care can
differ between nations, the facility characteristics affect-
ing the use of APMs may be similar. Understanding the
facility characteristics affecting use of these drugs in
nursing homes can help inform policies and research
internationally. It is crucial to consider the potential
causes of overuse. In a campaign to reduce use in Eng-
land, it was noted that although good practice guidelines
are available, there has not been a clear integration into
clinical practice [13]. Looking at the facility characteris-
tics may help to provide insight into the difficulties of
translating clinical guidelines into practice. It is import-
ant to look at international approaches to the use of
APMs in the treatment of patients with dementia in
order to find the safest and most effective treatment for
this population.
Limitations
This study has several important limitations. First, the
studies included in the review did not sample the same
population; some included national data and others data
from a single state. Second, it was difficult to systematic-
ally judge the quality of the articles because observa-
tional studies of several varieties were included. Finally,
the expert consultant panel used in the modified Delphi
process was comprised of providers from limited geo-
graphical areas (Arizona, Washington, Pennsylvania, Illi-
nois, South Carolina and Oregon). This may have
resulted in APM use etiology suggestions consistent with
nursing homes in those areas, which may have differed
from other regions. Surveying health professionals across
the nation would result in a more representative and po-
tentially less biased perspective. Importantly, this review
was constrained to facility level features, many of which
are not remediable.
Conclusion
The use of APMs in U.S. nursing homes was found to
vary based on physical, staffing, occupancy, market, and
quality characteristics. Due to the dangerous health out-
comes associated with use of APMs in the elderly, it is
critical that unnecessary use be reduced. The facility
characteristics outlined in this review may serve as a
basis for meaningful interventions to improve the quality
of care in nursing homes across the nation and abroad.
Additional file
Additional file 1: Database search strategies. (DOCX 32 kb)
Additional file 2: PRISMA checklist. (DOCX 22 kb)
Additional file 3: Table of included studies by time period.
(DOCX 25 kb)
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